📣 VC round data is live. Check it out!
- Public Comps
- Ypsomed
Ypsomed Valuation Multiples
Discover Ypsomed's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Sysmex, Teleflex, Abbott India, Getinge and more.
Ypsomed Overview
About Ypsomed
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
Founded
2003
HQ

Employees
2.8K
Website
Financials (LTM)
EV
$6B
Valuation Multiples
Start free trialYpsomed Financials
Ypsomed reported last 12-month revenue of $924M and EBITDA of $409M.
In the same LTM period, Ypsomed generated $403M in gross profit, $409M in EBITDA, and $273M in net income.
Revenue (LTM)
Ypsomed P&L
In the most recent fiscal year, Ypsomed reported revenue of $930M and EBITDA of $415M.
Ypsomed is profitable as of last fiscal year, with gross margin of 43%, EBITDA margin of 45%, and net margin of 30%.
Financial data powered by Morningstar, Inc.
Ypsomed Stock Performance
Ypsomed has current market cap of $6B, and enterprise value of $6B.
Market Cap Evolution
Ypsomed's stock price is $430.20.
Ypsomed share price decreased by 4.1% in the last 30 days, and by 20.1% in the last year.
Ypsomed has an EPS (earnings per share) of $21.47.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $6B | -0.0% | -4.1% | 21.8% | -20.1% | $21.47 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialYpsomed Valuation Multiples
Ypsomed trades at 6.4x EV/Revenue multiple, and 14.6x EV/EBITDA.
EV / Revenue (LTM)
Ypsomed Financial Valuation Multiples
As of June 3, 2026, Ypsomed has market cap of $6B and EV of $6B.
Ypsomed has a P/E ratio of 20.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ypsomed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Ypsomed Margins & Growth Rates
Ypsomed decreased revenue by 3% and EBITDA by 4% in the last fiscal year.
In the most recent fiscal year, Ypsomed reported gross margin of 43%, EBITDA margin of 45%, and net margin of 30%.
Ypsomed Margins
Ypsomed Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Ypsomed Operational KPIs
Ypsomed's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.0M for the same period.
Ypsomed's Rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ypsomed's Rule of X is 38% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Ypsomed Competitors
Ypsomed competitors include Sysmex, Teleflex, Abbott India, Getinge, Sectra, Andon Health, Bausch + Lomb, Novanta, Asahi Intecc and Snibe.
Most Ypsomed public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.7x | 1.7x | 7.2x | 8.6x | |||
| 4.0x | 3.7x | 13.0x | 13.1x | |||
| 7.7x | 7.6x | 24.6x | 27.7x | |||
| 1.6x | 1.6x | 8.6x | 8.6x | |||
| 16.6x | 16.4x | 64.0x | 62.6x | |||
| 25.2x | - | 12.7x | - | |||
| 2.0x | 1.9x | 11.4x | 10.7x | |||
| 6.0x | 5.8x | 26.7x | 25.4x | |||
This data is available for Pro users. Sign up to see all Ypsomed competitors and their valuation data. Start Free Trial | ||||||
Investments by Ypsomed
Ypsomed has invested in 1 company to date.
Latest investment by Ypsomed was on April 13th 2021. Ypsomed invested in CeQur Simplicity in their $115M Series C round (EV/Revenue multiple available to Pro users).
Latest Investments by Ypsomed
| Description | CeQur Simplicity is a Zug, Switzerland-based medical device company developing wearable bolus insulin delivery patches for type 2 diabetes management. The Simplicity platform delivers up to three days of automated dosing via button-activated patches, distributed through partnerships with pharmaceutical firms in Europe and the United States. |
| HQ Country | |
| HQ City | Lucerne |
| Deal Date | 13 Apr 2021 |
| Round | Series C |
| Raised | $115M |
| Investors | Credit Suisse Entrepreneur Capital; Endeavour Vision; Federated Kaufmann Fund; GMS Capital Partners; Kingdon Capital; Schroders; Tandem Diabetes Care; VI Partners; Ypsomed |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Ypsomed investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ypsomed
| When was Ypsomed founded? | Ypsomed was founded in 2003. |
| Where is Ypsomed headquartered? | Ypsomed is headquartered in Switzerland. |
| How many employees does Ypsomed have? | As of today, Ypsomed has over 2K employees. |
| Who is the CEO of Ypsomed? | Ypsomed's CEO is Simon Michel. |
| Is Ypsomed publicly listed? | Yes, Ypsomed is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Ypsomed? | Ypsomed trades under YPSN ticker. |
| When did Ypsomed go public? | Ypsomed went public in 2004. |
| Who are competitors of Ypsomed? | Ypsomed main competitors include Sysmex, Teleflex, Abbott India, Getinge, Sectra, Andon Health, Bausch + Lomb, Novanta, Asahi Intecc, Snibe. |
| What is the current market cap of Ypsomed? | Ypsomed's current market cap is $6B. |
| What is the current revenue of Ypsomed? | Ypsomed's last 12 months revenue is $924M. |
| What is the current revenue growth of Ypsomed? | Ypsomed revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Ypsomed? | Current revenue multiple of Ypsomed is 6.4x. |
| What is the current EBITDA of Ypsomed? | Ypsomed's last 12 months EBITDA is $409M. |
| What is Ypsomed's EBITDA margin? | Ypsomed's last 12 months EBITDA margin is 44%. |
| What is the current EV/EBITDA multiple of Ypsomed? | Current EBITDA multiple of Ypsomed is 14.6x. |
| What is the current FCF of Ypsomed? | Ypsomed's last 12 months FCF is $73M. |
| What is Ypsomed's FCF margin? | Ypsomed's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Ypsomed? | Current FCF multiple of Ypsomed is 81.8x. |
| How many companies Ypsomed has acquired to date? | Ypsomed hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Ypsomed has invested to date? | As of June 2026, Ypsomed has invested in 1 company. |
| What was the last Ypsomed investment? | On 13th April 2021 Ypsomed invested in CeQur Simplicity, participating in a $115M Series C round, alongside Credit Suisse Entrepreneur Capital, Endeavour Vision, Federated Kaufmann Fund, GMS Capital Partners, Kingdon Capital, Schroders, Tandem Diabetes Care, and VI Partners. |
| In what companies Ypsomed invested in? | Ypsomed invested in CeQur Simplicity. |
See public comps similar to Ypsomed
Lists including Ypsomed
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
